Company intelligence / Profile preview

Guangzhou Bairui Biomedical Technology

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Guangzhou Bairui Biomedical Technology has at least three investigator-initiated early phase 1 clinical trials ongoing in China for its BGT007 and BGT007H cell therapy platforms targeting recurrent/metastatic digestive tract tumors and nasopharyngeal carcinoma. Clinical results to date are focused on safety and initial efficacy evaluation, with trials actively recruiting as of July 2025[7].

Therapeutic areas: HematologyOncology
Modalities: Cell therapy
Industry: Biotech

Partnerships

Affiliated Hospital of Xuzhou Medical University

Beyond the preview

Go deeper on Guangzhou Bairui Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Bairui Biomedical Technology.

Explore the full profile